Top Markets
Coin of the day
Daiichi Sankyo Company, Limited Daiichi Sankyo Company, Limited

Daiichi Sankyo Company, Limited

DSNKY
Rangering i aksjer #660
Daiichi Sankyo Company, Limited researches and develops, manufactures, imports,... Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, markets, and sells pharmaceutical products worldwide. The company offers trastuzumab deruxtecan, an anti-cancer agent and anti-HER2 antibody drug conjugate; mirogabalin for pain treatment; teneligliptin/canagliflozin for type 2 diabetes mellitus treatment; lacosamide anti-epileptic agent; prasugrel, an antiplatelet agent; denosumab for osteoporosis and bone disorders; teneligliptin for type 2 diabetes mellitus treatment; edoxaban, an anticoagulant; esomeprazole for ulcer treatment; memantine for treating Alzheimer's disease; and laninamivir for anti-influenza treatment. It also provides olmesartan, an antihypertensive agent; levofloxacin, an antibacterial agent; pravastatin for hypercholesterolemia treatment; and loxoprofen, an anti-inflammatory analgesic. In addition, the company offers colesevelam for treating hypercholesterolemia and type 2 diabetes mellitus treatment; and ferric carboxymaltose and iron sucrose injections for treating anemia. Further, it provides Lulu, a combination cold remedy; Loxonin S, an antipyretic analgesic /anti-inflammatory analgesic; Transino for melasma improvement and treating against spots and freckles; Minon, a skincare product; and Breath Labo and Clean Dental oral care products, as well as Silodosin for dysuria; Gefitinib for malignant tumours; Bicalutamide for prostate cancer; and Tamoxifen, an anti-breast cancer agent. Additionally, the company offers adsorbed cell culture-derived influenza, influenza HA, measles rubella combined, and mumps vaccines. It also provides pharmaceuticals and drugs for animals, cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, and intermediates. It has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. The company was founded in 1899 and is headquartered in Tokyo, Japan.
Aksjekurs
$17.64
Markedsverdi
$32.65B
Endring (1 dag)
-3.24%
Endring (1 år)
-23.70%
Land
JP
Handel Daiichi Sankyo Company, Limited (DSNKY)

Kategori

Inntekter for Daiichi Sankyo Company, Limited (DSNKY)
Inntekter i Dec 2025 TTM: $13.20B
Ifølge de nyeste økonomiske rapportene til Daiichi Sankyo Company, Limited er selskapets nåværende inntekter (TTM) $13.20B. I 2024 hadde selskapet inntekter på $10.58B en økning sammenlignet med inntektene i 2023, som var $9.63B. Inntektene er det totale beløpet et selskap genererer fra salg av varer eller tjenester. I motsetning til fortjeneste trekkes ingen kostnader fra.
Inntektshistorikk for Daiichi Sankyo Company, Limited fra 2000 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
2026 (TTM) $13.20B 4.91%
2025 $12.58B 18.91%
2024 $10.58B 9.90%
2023 $9.63B 12.20%
2022 $8.58B -1.25%
2021 $8.69B -4.84%
2020 $9.13B 9.03%
2019 $8.38B -7.32%
2018 $9.04B 5.39%
2017 $8.58B -2.19%
2016 $8.77B 14.38%
2015 $7.67B -29.30%
2014 $10.84B 2.39%
2013 $10.59B -6.41%
2012 $11.31B -3.05%
2011 $11.67B 14.54%
2010 $10.19B 19.06%
2009 $8.56B -3.04%
2008 $8.83B 12.02%
2007 $7.88B 0.11%
2006 $7.87B 43.33%
2005 $5.49B -4.11%
2004 $5.73B 18.80%
2003 $4.82B 16.37%
2002 $4.14B -4.69%
2001 $4.35B -24.27%
2000 $5.74B 0.00%
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
$65.18B 393.73%
US
$58.74B 344.95%
GB
$94.19B 613.52%
US
$61.16B 363.29%
US
$56.15B 325.33%
CH